Abstract:Recent advancements in comprehending peripheral T-cell lymphomas (PTCLs) validate and broaden our perspective, highlighting their diverse nature and the varying molecular mechanisms underlying the entities. Based on a comprehensive accumulated understanding, the PTCLs currently overcome the most challenging features of any disease: rarity, incredible heterogeneity, and a lack of any established standard of care. The treatments deployed in the front-line are extrapolated from regimens developed for other diseases. The recent approval of the three drugs brentuximab vedotin (BV), pralatrexate, and belinostat for patients with relapsed or refractory disease has provided clues about pathophysiology and future directions, though challenges satisfying post-marketing requirements (PMR) for those accelerated approvals have led to one of those drugs being withdrawn and put the other two in jeopardy. Edits of the front-line regimens, often called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-plus approaches, look more like CHOP-minus strategies, as the toxicity of five-drug regimens often reduces the dose intensity of the added 'novel' drug, nullifying any hope of an advance. The turmoil in the field produced by the aforementioned, coupled with an ever-changing classification, has left the field uncertain about the path forward. Despite these challenges, empiric findings from studies of novel drug approaches, coupled with a logic emerging from studies of PTCL lymphomagenesis, have begun to illuminate, albeit faintly for some, a potential direction. The empiric finding that drugs targeting the discrete components of the PTCL epigenome, coupled with the description of multiple mutations in genes that govern epigenetic biology, offers, at the very least, an opportunity to finally be hypothesis-driven. The most recent recognition that the only combination of drugs shown to markedly improve progression-free survival (PFS) in patients with relapsed disease is one based on dual targeting of different and discrete components of that epigenetic biology has established a possibility that circumnavigating chemotherapy addition studies is both plausible, feasible, and likely the best prospect for a quantum advance in this disease. Herein, we analyze PTCL through a 2025 lens, highlighting and underscoring walls that have impeded progress. We will critically explore all the clues and the panoramic view of PTCL research.

[A case of bronchogenic cyst in the posterior mediastinum with high level of serum SCC antigen].

Genetic Landscape of Peripheral T-Cell Lymphoma

Research Progress in Treatment of Peripheral T-cell Lymphoma

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)

Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine

Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

In sight but out of mind.

Peripheral T-cell lymphoma: From biology to practice to the future

Effect of the M(s) transformation temperature on the wear behaviour of NiTi shape memory alloys for articular prosthesis.

New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies

From empiric to mechanism-based therapy for peripheral T cell lymphoma

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Epidemiology and Pathology of T- and NK-Cell Lymphomas

Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles

How I treat the peripheral T-cell lymphomas

A practical approach to the modern diagnosis and classification of T-and NK-cell lymphomas

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Peripheral T-cell lymphoma: Are all patients high-risk?

Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas